Clinical Trials

Shutterstock photo (RTTNews.com) – The following are some of the biotech stocks that made their way onto the Day’s Gainers Losers’ list of September 28, 2017. GAINERS 1. Zynerba Pharmaceuticals Inc. (ZYNE) Gained 52.50% to close Thursday’s (Sep.28) trading at $9.44. News: The Company reported positive top line results from its phase II trial of […]

by

ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced positive […]

by

NEW YORK, September 19, 2017 : The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. Nevertheless, […]

by

Intec Pharma Ltd (NASDAQ:NTEC) stock price target has been raised by Oppenheimer to $15.00 from $10.00 while maintaining the Outperform rating. The analyst Jay Olson has noted that the shares are up 60% since June and expects further upside as Accordion resonates with investors. Further the analyst Olson noted the clinical and operational progress that […]

by

It may be one of the world’s oldest drugs, but cannabis has caught the world unprepared. After 80 years of draconian prohibition, the tide has suddenly turned. Medicinal cannabis is flooding in and overwhelming the medical establishment, as patients clamour for it, many convinced it is a harmless cure-all to their ills. Some 2.3 million […]

by

NEW YORK, September 19, 2017 /PRNewswire/ — The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. […]

by

TORONTO, ONTARIO–(Marketwired – Sept. 19, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation (“SCRF”), under which Revive will acquire […]

by

Medicine bottle image: monicore A small observational trial of the use of medicinal cannabis extracts in treating autism has returned positive results. Australia’s Zelda Therapeutics sponsored a trial in Chile involving 21 patients, who were treated over at least three months. According to the company, results of the trial indicate cannabis extracts are more effective […]

by

TORONTO, ONTARIO–(Marketwired – Sept. 19, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation (“SCRF”), under which Revive will acquire […]

by

NEW YORK, September 19, 2017 /PRNewswire/ — The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. […]

by

Whole-plant marijuana and its products are already used during palliative care outside of the traditional hospice and hospital settings. Santa Cruz, California, is home to the Wo/Men’s Alliance for Medical Marijuana, a cannabis collective that has been compared to a traditional hospice. Director Valerie Corral helped pass the country’s first medical cannabis law in part […]

by

A phase 2 trial of Zynerba Pharmaceuticals’ transdermal cannabinoid candidate has missed all its endpoints. The failure of the study to hit a single goal or show a dose response raises big doubts about the drug’s prospects—and wiped more than 55% off Zynerba’s stock price. Investigators enrolled 188 adults with refractory epilepsy with focal seizures and […]

by

August 24, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks releases a snapshot of companies in the cannabis/marijuana sector that are developing methods for cannabinoids to be used as medicine and treatments for cancer, epilepsy, concussions and traumatic brain injury. The Hemp Business Journal projects that the […]

by